ACRUX LIMITED — Capital/Financing Update 2017

Apr 25, 2017

ACRUX (ACR) - ASX ANNOUNCEMENT

26 APRIL 2017

AXIRON ® NET SALES, QUARTER TO 31 MARCH 2017

==> picture [483 x 11] intentionally omitted <==

Acrux (ASX: ACR) today confirmed that Eli Lilly and Company reported global Axiron net sales of US$27.3 million in its financial results for the quarter ending 31 March 2017, down from US$37.0 million for the previous corresponding quarter to 31 March 2016.

Axiron net sales for the 2017 financial year to date (YTD) and 2016 financial year are shown in the following table:

Q1 FY2017	Q2 FY2017	Q3 FY2017		YTD FY2017
US$39.0m	US$39.9m	US$27.3m		US$106.2m
Q1 FY2016	Q2 FY2016	Q3 FY2016	Q4 FY2016	Total FY2016
US$41.4m	US$41.6m	US$37.0m	US$29.3m	US$149.3m

To date, there has been no launch of a generic of Axiron.

For further information, contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising specialty and generic topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of pharmaceutical products in the US and Europe using the Patchless Patch™, a fast-drying and invisible topical application technology. Marketed products include Axiron[®] , Evamist[®] and Lenzetto[®] . More recently, in addition to specialty products, Acrux has identified and initiated development of a range of generic products. Acrux is leveraging its onsite laboratories, GMP manufacturing suite, clinical and commercial experience to bring more products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au

==> picture [541 x 82] intentionally omitted <==